Revisiting a distinct entity in pulmonary vascular disease: Chronic thromboembolic pulmonary hypertension (cteph)

Munish Sharma, Deborah Jo Levine

Research output: Contribution to journalReview articlepeer-review

Abstract

Chronic thromboembolic pulmonary hypertension (CTEPH) is a specific type of pulmonary hypertension (PH) and the major component of Group 4 pulmonary hypertension (PH). It is caused by pulmonary vasculature obstruction that leads to a progressive increase in pulmonary vascular resistance and, ultimately, to failure of the right ventricle. Pulmonary thromboendarterectomy (PEA) is the only definitive therapy, so a timely diagnosis and early referral to a specialized PEA center to determine candidacy is prudent for a favorable outcome. Percutaneous balloon pulmonary angioplasty (BPA) has a potential role in patients unsuitable for PEA. Medical therapy with riociguat is the only PH-specific medical therapy currently approved for the treatment of inoperable or persistent CTEPH. This review article aims to revisit CTEPH succinctly with a review of prevailing literature.

Original languageEnglish (US)
Article number355
JournalMedicina (Lithuania)
Volume57
Issue number4
DOIs
StatePublished - Apr 2021

Keywords

  • Chronic thromboembolic pulmonary hypertension
  • Computed tomography pulmonary angiography
  • Percutaneous balloon pulmonary angioplasty
  • Pulmonary angiography
  • Pulmonary embolism
  • Pulmonary thromboendarterectomy
  • Riociguat
  • Ventilation-perfusion lung scan

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Revisiting a distinct entity in pulmonary vascular disease: Chronic thromboembolic pulmonary hypertension (cteph)'. Together they form a unique fingerprint.

Cite this